Johnson & Johnson
JNJ
Below: live stock price for Johnson & Johnson (JNJ), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Johnson & Johnson (JNJ) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 138,200 people. Over the past year JNJ traded between 184.66 and 281.07 USD. Trailing P/E sits near 38.78 on a market cap of about 615.87B USD. It currently yields 2.10% in dividends.
- Prev close
- $253.28
- Volume (24h)
- $1.63B
- Market cap
- $615.87B
- Currency
- USD
Score
46/ 100 · Mixed
- Value7
- Quality83
- Momentum55
- Growth19
- Risk71
- Dividend43
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 255.3968 -0.06%
- +20 bars
- 255.1717 -0.15%
- +60 bars
- 255.0847 -0.19%
- +120 bars
- 255.0815 -0.19%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0258 USD.
Interpretation
Composite signals look mixed. Strength: quality with weakness: valuation. Price sits near the lower third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value7/100
Value looks fragile — driven by P/E (38.78).
P/E:38.78P/B:7.24PEG:2.8 - Quality83/100
Quality looks strong — driven by Gross margin (67.75%).
Profit margin:16.20%Gross margin:67.75% - Momentum55/100
Momentum looks mixed — driven by 52w change (31.92%).
52w change:31.92% - Growth19/100
Growth looks fragile — driven by Earnings growth (-96.00%).
Revenue growth:5.90%Earnings growth:-96.00% - Risk71/100
Risk looks solid — driven by Debt / equity (57.71).
Beta:0.21Debt / equity:57.71Short interest:1.02% - Dividend43/100
Dividend looks weak — driven by Payout ratio (60.72%).
Dividend yield:2.10%Payout ratio:60.72%
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 20.4%
- Max drawdown
- -11.0%
- Below period high
- -9.1%
- Best day
- +3.99%
- Worst day
- -5.73%
- Up days
- 53%
- Current streak
- 1 up
- Typical day swing
- 1.8%
- Volume vs average
- +9%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 281.07 high → 245.17 low · 60 bars
- ResistanceFib +161.8% extensionnot reached339.1562 USD+32.71% from current
- ResistanceFib +100% extensionnot reached316.97 USD+24.03% from current
- ResistanceFib +61.8% extensionnot reached303.2562 USD+18.66% from current
- ResistanceFib +27.2% extensionnot reached290.8348 USD+13.80% from current
- ResistanceFib 23.6% retracementtested 10×272.5976 USD+6.67% from current
- ResistanceFib 38.2% retracementtested 21×267.3562 USD+4.62% from current
- ResistanceFib 50% midpointtested 7×263.12 USD+2.96% from current
- ResistanceFib 61.8% retracementtested 13×258.8838 USD+1.30% from current
- Current255.56 USD
- SupportFib 78.6% retracementNearesttested 8×252.8526 USD-1.06% from current
- SupportFib −27.2% extensionnot reached235.4052 USD-7.89% from current
- SupportFib −61.8% extensionnot reached222.9838 USD-12.75% from current
- SupportFib −100% extensionnot reached209.27 USD-18.11% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $281.07
- 52w low
- $184.66
- 52w change
- 31.92%
- Day high
- $257.51
- Day low
- $254.00
- P/E (TTM)
- 38.78
- Forward P/E
- 21.83
- PEG
- 2.8
- Price / Book
- 7.24
- Beta (5Y)
- 0.21
- Enterprise value
- 644.15B
- EV / Revenue
- 6.49
- EV / EBITDA
- 18.86
- EPS (TTM)
- $6.59
- Forward EPS
- $11.71
- Dividend yield
- 2.10%
- Dividend rate
- $5.36
- Payout ratio
- 60.72%
- Revenue (TTM)
- 99.33B
- EBITDA
- 34.15B
- Total cash
- 20.76B
- Total debt
- 49.04B
- Debt / Equity
- 57.71
- Profit margin
- 16.20%
- Gross margin
- 67.75%
- Shares outstanding
- 2.41B
- Float
- 2.41B
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Analyst & Risk
- Beta (vs S&P 500)
- 0.21
- very stable
- 52-week change
- 31.92%
- Short % of float
- 1.02%
- Short ratio (days)
- 3.46
- Debt / Equity
- 57.71
- very high leverage
- PEG ratio
- 2.8
- richly valued
- EV / Revenue
- 6.49
- EV / EBITDA
- 18.86
- Revenue growth
- 5.90%
- Earnings growth
- -96.00%
- EBITDA
- 34.15B
- Total cash
- 20.76B
- Total debt
- 49.04B
- Insider holdings
- 0.05%
- Institutional
- 76.75%
Recent rating changes
- 2026-10-16Wells FargoOverweight → Overweightmain
- 2026-10-15Morgan StanleyOverweight → Overweightmain
- 2026-10-14Leerink PartnersOutperform → Outperformmain
- 2026-10-14Wells FargoOverweight → Overweightmain
- 2026-10-14RBC CapitalOutperform → Outperformmain
- 2026-10-07GuggenheimBuy → Buyreit
- 2026-10-06RBC CapitalOutperform → Outperformmain
- 2026-10-05CitigroupBuy → Buymain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-13
- Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PXN-PX2026-08-11
- Corporate Changes & Voting Matters8-K2026-08-04
- Corporate Changes & Voting Matters8-K2026-07-29
- Corporate Changes & Voting Matters8-K2026-07-28
- Periodic Financial Reports10-Q2026-07-23
- Corporate Changes & Voting Matters8-K2026-07-15
- Annual report of employee stock purchase11-K2026-06-25
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-27
- Corporate Changes & Voting Matters8-K2026-04-28
- Periodic Financial Reports10-Q2026-04-22
- Corporate Changes & Voting Matters8-K2026-04-14
Recent news
- Should You Invest in This Dividend King on the Dip?Motley Fool1d ago
- Procter & Gamble Has Raised Its Dividend for 70 Years. These 2 Stocks Share Its Advantage24/7 Wall St.1d ago
- AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?24/7 Wall St.1d ago
- When the Stock Market Gets Dangerous, These 6 Investments Have a History of Holding UpMotley Fool1d ago
- MarketBeat Week in Review – 10/12 - 10/16MarketBeat1d ago
- Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.Motley Fool1d ago
- What Was Eli Lilly Telling You Before Its Stock Ran?Trefis1d ago
- 3 Great Biotech Stocks To Watch In October 2026Simply Wall St.2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,431 USD-1.27%
- 7203.TToyota Motor Corporation3,075 USD-0.61%
- 9984.TSoftBank Group Corp.4,732 USD-4.29%
- 6758.TSony Group Corporation3,946 USD-0.33%
- 6861.TKeyence Corporation79,950 USD-1.00%
- NVDANVIDIA Corporation214.13 USD-1.43%
- AAPLApple Inc.343.46 USD+0.43%
- GOOGLAlphabet Inc.340.59 USD-2.47%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.